Clinical Trials Logo

Gastric Neoplasm clinical trials

View clinical trials related to Gastric Neoplasm.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06362070 Recruiting - Gastric Cancer Clinical Trials

Comparison of Outcomes of Multiple Platforms for Assisted Robotic - Gastrectomy

Start date: January 31, 2024
Phase: N/A
Study type: Interventional

The object of this exploratory clinical trial is to evaluate intra and post-operative complications in a population that underwent Robotic Gastrectomy, with multiple platforms: - DaVinci; - Hugo; - Versius. This study is divided into two phases: in the first phase, gastrectomy will be performed using both the new platforms (Hugo and Versius) and the standard platform (Da Vinci), to evaluate the feasibility of the surgical procedure. In the second phase, the three platforms will be compared to evaluate any differences in the learning curve for an upper-GI surgeon, expert in laparoscopic surgery but not with robotic one. The questions it aims to answer are: - Are differences (intra-operative, post-operative, oncological, functional, technical, and economic) among the three different platforms observable? - Are there any differences between the three platforms related to the learning curve for surgeons? Participants will be enrolled, after obtaining informed consent, in one of the following cohorts: 1. surgery with the daVinci platform; 2. surgery with the Hugo platform; 3. surgery with the Versius platform.

NCT ID: NCT06342427 Recruiting - Gastric Cancer Clinical Trials

Stomach Cancer Exosome-based Detection

DESTINEX
Start date: March 15, 2023
Phase:
Study type: Observational

Gastric cancer continues to have a poor prognosis primarily due to the inability to detect it in its early stages. This study will develop and validate a blood assay to facilitate the non-invasive detection of gastric cancer.

NCT ID: NCT06028737 Recruiting - Gastric Cancer Clinical Trials

Total Neoadjuvant Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer

OCTASUR
Start date: August 25, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

The main goal of this study is to investigate the histopathological regression rate in patients with locally advanced gastric and gastroesophageal adenocarcinoma without previous treatment who will be prospectively randomized into two groups to undergo one of two chemotherapy regimens, followed by surgery: 1. 8 cycles of Total Neoadjuvant ChemoTherapy (TNT) with 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin and Docetaxel (FLOT) followed by surgery. 2. 4 cycles of Neoadjuvant FLOT chemotherapy scheme preoperatively and 4 adjuvant FLOT cycles postoperatively.

NCT ID: NCT05804331 Recruiting - Gastric Cancer Clinical Trials

The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study

ANZ UGI
Start date: March 14, 2023
Phase:
Study type: Observational [Patient Registry]

To determine the long term outcomes of Endoscopic Submucosal Dissection (ESD), Endoscopic Full Thickness Resection (EFTR) and Submucosal-Tunnelling Endoscopic Resection (STER) for upper gastrointestinal neoplastic lesions

NCT ID: NCT05688020 Recruiting - Clinical trials for Esophageal Neoplasms

Tranexamic Acid During Upper GI Endoscopic Resection Procedures

Start date: February 1, 2023
Phase: Phase 4
Study type: Interventional

Endoscopic resection of gastrointestinal lesions may prevent cancer. However, resection is associated with adverse events such as bleeding. Tranexamic acid (TXA) is a synthetic derivative of lysine that exerts antifibrinolytic effects and may prevent bleeding. The investigators aim to evaluate the effect of local TXA on preventing intraprocedural and postprocedural bleeding in patients undergoing endoscopic mucosal resection (EMR) of upper gastrointestinal lesions.

NCT ID: NCT04780256 Recruiting - Clinical trials for Esophageal Neoplasms

Endoscopic Resection of Gastrointestinal Neoplasms

Start date: March 15, 2021
Phase:
Study type: Observational

The study aims to retrospectively investigate the endoscopic resection procedures of cancerous and precancerous lesions of the upper and lower digestive tract in order to evaluate the efficacy and safety outcomes and to compare different resection techniques. In particular, the resection techniques investigated will be mucosectomy, en bloc and piecemeal, endoscopic submucosal dissection (ESD) and its variants, full-thickness resection. The anatomical districts involved will be the esophagus, stomach, duodenum, colon and rectum.

NCT ID: NCT04622098 Recruiting - Clinical trials for Esophageal Neoplasms

Prevalence of Sub-epithelial Lesions Among Patients Undergoing EGDs in Egypt

Start date: November 18, 2020
Phase:
Study type: Observational

Subepithelial lesions (SEL) are incidentally observed in the stomach of about 0.3% of middle-aged men and women; half of these are neoplastic. The incidence of subepithelial tumors (SET) of gastrointestinal (GI) origin has risen twofold to fivefold within the past 30 years.The etiology of most SMTs cannot easily be determined by endoscopy. So, we aim to estimate the prevalence and types of sub-epithelial lesions among patients undergoing EGDs in Egypt.

NCT ID: NCT04557969 Recruiting - Gastric Cancer Clinical Trials

Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis

Start date: December 18, 2020
Phase:
Study type: Observational

Objective: To follow people with GISTs and collect tumor tissue so that it can be studied in the lab. Eligibility: People age 6 and older who have a GIST. Design: Participants will be screened with a review of their medical records and samples. Participants will enroll in 1 other NIH study, and may be asked to enroll in 2 other optional NIH studies. Participants will have a medical history and physical exam. Data about how they function in their daily activities will be obtained. Participants may speak with a genetic counselor. They may have genetic testing. Participants will give blood samples. They may have a cheek swab. For this, small brush will be rubbed against the inside of the cheek. Participants may have a computed tomography (CT) scan of the chest, abdomen, and pelvis. Or they may have a CT scan of the chest and magnetic resonance imaging (MRI) of the abdomen and pelvis. Participants will be monitored every 6-12 months at the NIH Clinical Center, for up to 10 years before having surgery. If they need surgery, it will be performed at the NIH. Then, they will be monitored every 6-12 months, for up to 5 years after surgery. If a participant has surgery, tumor tissue samples will be taken. If a participant does not need surgery, their participation will end after 10 years. If they have surgery, the 5-year monitoring period will restart after each surgery.

NCT ID: NCT04484311 Recruiting - Clinical trials for Colorectal Neoplasms

Non-curative ESDs: Assessing the Rates and Risk Factors for Residual Neoplasia

NC-ESD
Start date: August 1, 2020
Phase:
Study type: Observational

Short and long outcomes of ESD are well described, particularly in Eastern series. However, the outcome of non-curative ESDs is scarcely reported in the west (particularly among non-gastric or submucosal lesions). Therefore, the aim of this project is to describe the European experience with non-curative ESDs, analysing all the consecutive ESDs performed in several reference centers, assessing the presence of residual lesion in the endoscopic follow-up or in the surgical specimen.

NCT ID: NCT04466631 Recruiting - Clinical trials for Esophageal Neoplasms

Health and Employment After Gastro Intestinal Surgery - HEAGIS2

HEAGIS2
Start date: June 15, 2020
Phase:
Study type: Observational

By using the M.A.D.I.T. methodology and the Dialogics science, SALVO Project aims to develop operational guidelines to support oncological target patients in the resumption of their daily post-operative activities. The research will implement an instrument for the purpose of measuring the health need of participants who are admitted to the surgical ward. Therefore, targeted interventions will be implemented with participants, and efficacy will be evaluated in order to define treatment guidelines. The principal aim of this study is to create a validated and replicable intervention model for supporting patients who undergone surgery for esophageal and gastro intestinal cancer.